Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231.
Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231.
复制标题
血浆P-tau亚型P-tau 181、P-tau 217和P-tau 231的六种Simoa检测的临床和分析比较。
DOI:
10.1186/s13195-021-00939-9
复制
发表时间:
2021-12-04
期刊:
影响因子:
--
通讯作者:
Teunissen CE
中科院分区:
文献类型:
--
作者:
Bayoumy S;Verberk IMW;den Dulk B;Hussainali Z;Zwan M;van der Flier WM;Ashton NJ;Zetterberg H;Blennow K;Vanbrabant J;Stoops E;Vanmechelen E;Dage JL;Teunissen CE
Studies using different assays and technologies showed highly promising diagnostic value of plasma phosphorylated (P-)tau levels for Alzheimer’s disease (AD). We aimed to compare six P-tau Simoa assays, including three P-tau181 (Eli Lilly, ADx, Quanterix), one P-tau217 (Eli Lilly), and two P-tau231 (ADx, Gothenburg). We studied the analytical (sensitivity, precision, parallelism, dilution linearity, and recovery) and clinical (40 AD dementia patients, age 66±8years, 50%F; 40 age- and sex-matched controls) performance of the assays. All assays showed robust analytical performance, and particularly P-tau217 Eli Lilly; P-tau231 Gothenburg and all P-tau181 assays showed robust clinical performance to differentiate AD from controls, with AUCs 0.936–0.995 (P-tau231 ADx: AUC = 0.719). Results obtained with all P-tau181 assays, P-tau217 Eli Lilly assay, and P-tau231 Gothenburg assay strongly correlated (Spearman’s rho > 0.86), while correlations with P-tau231 ADx results were moderate (rho < 0.65). P-tau isoforms can be measured robustly by several novel high-sensitive Simoa assays. The online version contains supplementary material available at 10.1186/s13195-021-00939-9.
登录
查看更多内容
DOI:
10.1084/jem.20200861
发表时间:
2020-11-02
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
Barthélemy NR;Horie K;Sato C;Bateman RJ
通讯作者:
Bateman RJ
影响因子:
12.7
作者:
Ashton NJ;Pascoal TA;Karikari TK;Benedet AL;Lantero-Rodriguez J;Brinkmalm G;Snellman A;Schöll M;Troakes C;Hye A;Gauthier S;Vanmechelen E;Zetterberg H;Rosa-Neto P;Blennow K
通讯作者:
Blennow K
DOI:
10.1016/s0140-6736(20)32205-4
发表时间:
2021-04-24
期刊:
Lancet (London, England)
影响因子:
--
作者:
Scheltens P;De Strooper B;Kivipelto M;Holstege H;Chételat G;Teunissen CE;Cummings J;van der Flier WM
通讯作者:
van der Flier WM
DOI:
10.1016/j.jalz.2011.03.005
发表时间:
2011-05
期刊:
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子:
--
作者:
McKhann GM;Knopman DS;Chertkow H;Hyman BT;Jack CR Jr;Kawas CH;Klunk WE;Koroshetz WJ;Manly JJ;Mayeux R;Mohs RC;Morris JC;Rossor MN;Scheltens P;Carrillo MC;Thies B;Weintraub S;Phelps CH
通讯作者:
Phelps CH
影响因子:
82.9
作者:
Thijssen, Elisabeth H.;La Joie, Renaud;Boxer, Adam L.
通讯作者:
Boxer, Adam L.